Uh oh. Hope everyone beezes passed that part about funding from the Gates Foundation.Antibodies may be a cure as well. Here is a segment on Tucker last night. I copied the conversation.
CARLSON: Now, the physician you just saw says he may have found some kind of cure for coronavirus. Dr. Glanville joins us now. Doctor, thanks so much for coming on. So, obviously, I should just say at the outset, we approach everything like this with skepticism and also with the mind of a non- scientist. So, explain for our audience, me what this is and why you think it works.
GLANVILLE: Sure. Thanks for having me on, Tucker. So what we have done is we've engineered neutralizing antibodies that go and block the virus, the coronavirus, if you were to zoom in on it, you would see a ring of spikes, and it uses those spikes to invade human cells.
We've identified a series of super potent antibodies that block those spikes and therefore make the virus no longer infectious.
CARLSON: So how -- I mean, is this something that is done to defeat other viruses?
GLANVILLE: Yes, so this is the thing that turned the tide against Ebola. Ebola used to be a death sentence, about 50 percent mortality rate and then once a good antibody neutralizing solution was made, then I think 94 percent of people can walk away.
So that transformed Ebola from a dangerous crisis to a manageable treatment. We've also got antibodies to treat rabies. We've got antibodies to treat RSV in babies.
Antibodies are used for anti-venom. So this is an extremely well established platform technology and it has the advantage that you can produce antibodies much faster and you can make a vaccine.
And as I'd heard you mentioned previously on all that modeling, every day counts, we're venting an incredible amount of money out of our economy and risking lives, and so you want to have a medicine as quickly as possible.
CARLSON: That's right. Well, that is exactly right. So assuming this does work, how long would it take to get from your lab to the public?
GLANVILLE: Well, yes, so to address the question of skepticism, I'm glad you brought that up. Our next move is we hand this off to the U.S. military, a consortium from the Gates Foundation and some private groups, and all of them are going to test the potency of neutralization of our therapeutic.
We're also working with Charles River Laboratories that runs safety in talks to make sure this stuff is safe to put into people. And we're going to go into a scaled-up manufacture.
So at that point, what you do is you do a Phase 1/2 human trial, and that's where I'm going to do that towards the end of the summer, around August. We're giving that to about 600 patients, an antibody you can give to a patient and it works within five to 10 days to protect them, whereas a vaccine, you know, you need six or seven weeks before the person is protected. So that's another advantage.
And as soon as we know that, A, it's safe, so people can take it without it hurting them, and B, that it's effective that they receive an antibody and they're no longer dying or getting much more sick, then at that point, you can release the drug through something called compassionate use.
This is something that was done also in the Ebola crisis where if you don't have something F.D.A. approved yet, but you've got proof of efficacy and there's nothing else good, you could start releasing that to masses.
CARLSON: Last super quick question because our segments on TV are not long enough really to explain something this complex and I know some of our viewers are going to want to follow up by searching online. If you wanted to type into Google a term that would get you to an explanation, a deeper explanation of what this is what would you type in?
GLANVILLE: I would type in centivax.com which is our website and has a whole bunch of information around monoclonal therapeutics.